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study was to evaluate these PQA measures and assess predictors of qualifying into 
these measures among Medicaid beneficiaries from 39 states in the US. Methods: 
Medicaid beneficiaries from 39 US states aged 5 to 50 years were identified in cal-
endar year 2008. Of these, beneficiaries who filled one or more prescriptions for 
COPD medications, dornase alfa, or nasal steroid medications were excluded from 
the analysis. Beneficiaries with at least three canisters of short-acting beta agonists 
within 90 days were identified as those with SAC. Of the beneficiaries with SAC, 
those who did not receive asthma controller therapy in the same 90 day period 
were identified as those with ACT. Predictors of SAC and ACT were identified in 
2007. Results: A total of 77,783 asthma patients were identified in 2008. On an 
average, the proportion of patients with SAC and ACT in each state was 36.51% and 
54.15% respectively. Higher age (OR:1.023; CI:1.022-1.024), male gender (OR:1.205; 
CI:1.180-1.230), Caucasian (OR:0.889; CI:0.873-0.906) and African American race 
(OR:0.799; CI:0.772-0.826), greater number of hospital visits (OR:1.034; CI:1.025-
1.042), and greater number of asthma-related office visits (OR:1.194; CI:1.185-1.204) 
were significant predictors of SAC. Lower age (OR:0.996; CI:0.995-0.998), male gender 
(OR:1.121; CI:1.085-1.159), Caucasian (OR:1.279; CI:1.241-1.319) and African American 
race (OR:1.067; CI:1.009-1.128), greater number of emergency room visits (OR:1.021; 
CI:1.017-1.026), and lower number of asthma-related office visits (OR:0.696; CI:0.686-
0.706) were significantly associated with ACT. ConClusions: Patient demographics 
and resource utilization in the previous year are significant predictors of SAC and 
ACT. Prescribers and payers should use these to identify patients with persistent 
asthma most likely to misuse SABA and who need more appropriate use of asthma 
controller therapy.
RespiRatoRy-Related disoRdeRs – Cost studies
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impRoving adheRenCe to seasonal alleRgiC Rhinitis (saR) pRaCtiCe 
guidelines: Budget impaCt analysis FoR an intRanasal FoRmulation 
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objeCtives: Allergic rhinitis (AR) affects 10-20% of the US population, with treat-
ment costs exceeding $6 billion annually. US practice guidelines suggest treatment 
with a combination of intranasal corticosteroids and antihistamines. MP29-02 is 
intranasal formulation of azelastine hydrochloride and fluticasone propionate in 
an advanced delivery system indicated for the relief of symptoms of seasonal AR 
(SAR). Patients treated with MP29-02 experience significantly greater symptom 
relief in comparison to first-line therapy in trials. OBJECTIVE: To use an economic 
model to calculate the per-member per-month (PMPM) budget impact on a US 
health insurer of moving MP29-02 from third-tier to second-tier pricing and reim-
bursement. Methods: Population is SAR sufferers seeking treatment. MP29-02 
is assumed to gain market share annually with second-tier pricing. Time horizon 
is one year and five years. Perspective is a US health plan with 500,000 enroll-
ees. BIA is a pharmacy cost impact model using data from literature and supplied 
by Meda. Model assumes 10% branded drug price inflation; 80% brand to generic 
share shift and 50% price reduction; tiered payer rebate percentages and patient 
copay amounts. Results: Estimated treated SAR population ranged from 63,165 at 
baseline to 68,630 in Year 5. Branded share of fluticasone-based products declined 
from 17% to 7%. Overall SAR treatment budget declined from $3.2 million annu-
ally at baseline to $3.1 million in Year 5 reflecting expected shift from branded to 
generic market share. According to baseline assumptions, marginal change in costs 
over the one-year time horizon from moving MP29-02 from third-tier to second-
tier pricing are $19,659 (< $0.01 PMPM). Costs associated with the 5-year horizon, 
given changes in market shares, are $97,342 ($0.01 PMPM). ConClusions: MP29-02 
offers an appropriate means of adhering to AR practice guidelines and improving 
outcomes, and this BIA model shows that the added costs of those benefits are 
minimal to US payers.
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objeCtives: Respiratory syncytial virus (RSV) is a primary cause of lower respir-
atory tract infection in infants and children and leads to substantial morbidity. 
Palivizumab is a monoclonal antibody demonstrated to significantly reduce the 
frequency of hospitalizations for RSV infection in high-risk populations, including 
preterm infants and children with bronchopulmonary dysplasia and congenital 
heart disease. National costs of implementing a childhood prophylaxis program 
have not been well characterized. The objective was to compare the financial impact 
of implementing a RSV prevention program in high-risk infants using palivizumab, 
to three established childhood prophylaxis programs in Mexico: 13-valent pneu-
mococcal conjugate vaccine (PCV13); quadrivalent human papillomavirus (HPV) 
vaccine; and Bordetella pertussis (B. pertussis) vaccine. Methods: A model was 
developed to estimate the one-year budget impact of palivizumab for the preven-
tion of severe RSV infection in high-risk populations in Mexico, from the national 
health care perspective. Model inputs were derived following a literature review on 
the health care system, and included the epidemiology of severe RSV infection in 
Mexico and Latin America, with appropriate Mexican resource utilization and cost 
estimates. Results: The cost of prophylaxis with palivizumab was approximately 
MXN$283 million. The corresponding costs for PCV13, HPV vaccine, and B. pertus-
sis vaccine were estimated at MXN$1.1 billion; MXN$579 million; and MXN$636 
million, respectively. Total disease cost estimates were MXN$878 million for RSV 
found in their countries of origin. A longer stay in the host country or being a child 
of immigrant parents is associated with increasing adaption to the new environ-
ment, and therefore the prevalence of asthma and allergies over time converge 
with the prevalence in the non-immigrant host population. Comparisons between 
populations in their countries of origin and those that emigrated vary depending on 
their level of development; more developed countries show higher rates of asthma 
and allergies. ConClusions: Preliminary findings suggest a strong influence of 
the environment on the development of asthma and allergies. The prevalence of 
asthma is generally higher in second generation immigrants. With length of stay 
the prevalence of asthma and allergies increases steadily. Further analysis should 
assess homogeneity across studies and obtain pooled risk estimates of migration 
status as a risk factor for asthma and allergies.
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objeCtives: Tobacco use remains the leading preventable cause of premature 
death worldwide. Survey-based smoking related data has been collected from China, 
Jordan, India, Taiwan, and Saudi Arabia between 2009-2012. Predictors of smoking 
within each country have been identified and recently published. The objective was 
to identify and compare smoking predictors that remain significant across coun-
tries after combining the data from various countries into one dataset. Methods: 
Survey questions included socio-demographic characteristics, history of tobacco 
smoking, and environmental determinants of smoking like family and peer tobacco 
use. Multivariate logistic regression was constructed to determine predictors of 
smoking in the past month vs. no smoking. Results: A total of 3,658 adults par-
ticipated in the survey. Forty four percent of the participants had smoked cigarettes 
in the past month. Females were less likely to smoke (OR= 0.30, 95% CI= 0.22-0.42), 
whereas adults older than 25 (OR= 1.63, 95% CI= 1.16-2.29) or working/studying 
in medical related field (OR= 2.08, 95% CI= 1.10-3.95) were more likely to smoke. 
Compared to China participants, those from India, Saudi Arabia, Taiwan were less 
likely to smoke (OR= 0.13, 95% CI= 0.06-0.27 for India, OR= 0.005, 95% CI= < .001-0.07 
for Saudi Arabia, and OR= 0.04, 95% CI= 0.002-0.94 for Taiwan) while no significant 
differences were observed with Jordan participants. Teachers’ anti-smoking mes-
sages significantly decreased the likelihood of smoking (OR= 0.35, 95% CI= 0.13-0.90). 
Social network, on the other hand, significantly increased the likelihood of smoking, 
especially among siblings (OR= 1.70, 95% CI= 1.25-2.31) and close friends (OR= 1.96, 
95% CI= 1.34-2.86). Other variables associated with smoking included experiences 
with dyspepsia, education level, grades, personal feelings in previous week, and 
other substance use experiences (alcohol/cigar/chewing tobacco). ConClusions: 
The high smoking prevalence observed documents the magnitude of problem across 
these five countries. Future research should aim to incorporate the predictors identi-
fied above to develop effective interventions.
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objeCtives: Clinical trials have demonstrated that daily LAMA therapy in patients 
with COPD can improve lung function and quality of life. When LAMAs are clini-
cally indicated, the three oral agents currently available include tiotropium bro-
mide (TIOB), glycopyrronium (GLYCO) and most recently aclidinium bromide (ACLB). 
Placebo controlled trials have demonstrated efficacy, but safety data from head to 
head comparative trials are limited. In the absence of such data, mixed treatment 
comparison (MTC) models are a widely accepted statistical method of generating 
comparative safety information on clinically relevant but rare adverse events. In 
this study, an indirect comparison on safety was undertaken between TIOB, GLYCO 
and ACLB. Methods: A systematic literature review of major English language 
databases was conducted from January 1992 to December 2013 for randomized pla-
cebo controlled trials evaluating at least one of the three agents in COPD. Bayesian 
MTC models were fitted to assess comparative safety based on major adverse 
cardiovascular events (MACE), acute urinary retention (AUR), glaucoma and all-
cause mortality. Outcomes were adjusted for treatment duration and presented 
as a relative risk (RR) against ACLB. Results: A total of 20 randomized trials met 
the inclusion criteria. Insufficient trial data were reported to allow an evaluation 
of AUR and glaucoma. There were no significant differences in the risk of MACE 
between TIOB vs. ACLB (RR= 1.11; 95%CrI: 0.14 to 11.5) as well as GLYCO vs. ACLB 
(RR= 3.5; 95%CrI: 0.34 to 52.7). Similarly, there were no significant differences in the 
risk of all-cause mortality between TIOB (1.11; 95%CrI: 0.16 to 7.7) and GLYCO (0.84; 
95%CrI: 0.08 to 8.3) relative to ACLB. However, the magnitude of the RR for MACE 
suggests the potential for an increased risk with GLYCO when used as an alterna-
tive to ACLB. ConClusions: The risk of MACE and all-cause mortality with ACLB 
is comparable to both TIOB and GLYCO in patients with COPD.
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evaluation oF phaRmaCy Quality allianCe (pQa) measuRes among 
mediCaid BeneFiCiaRies with peRsistant asthma
Datar M., Null K.D, Banahan B.F.
University of Mississippi, University, MS, USA
objeCtives: The ‘suboptimal asthma control’ (SAC) and the ‘absence of controller 
therapy’ (ACT) measures endorsed by the Pharmacy Quality Alliance evaluate inap-
propriate medication taking behavior in patients with asthma. The purpose of this 
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the introduction of PCV7, net costs averted are in the range of $5 million as a result 
of the implementation of PCV7 universal vaccination in Alberta. Over the time 
period, direct protection resulted in net cost savings of $2.6 million, and indirect 
benefits $2.4 million; the indirect benefits derived by elderly populations were more 
than one third of the total benefits derived across the population. ConClusions: 
This study is unique in that it uses validated surveillance data from Alberta to 
retrospectively assess the economic benefit of a public health policy, and describes 
the distribution of benefits across different segments of the population. From 2003 
to 2008, the cumulative cost impact of introducing PCV7 in the childhood immu-
nization program to the Alberta health system is approximately $5 million, half of 
which were a result of herd immunity.
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objeCtives: In pharmaceutical comparative effectiveness studies, patients fre-
quently discontinue drug treatments soon after initiation, potentially biasing esti-
mated costs attributed to treatments. A partitioned data structure may facilitate 
estimating costs in the presence of censoring. We compared health care utilization 
costs for two chronic obstructive pulmonary disease (COPD) treatments over a one-
year period using intent-to-treat (ITT) and as protocol (AP) approaches. Methods: 
Claims data from two managed care health plans from July 2004 through September 
2013 was used to compare annual health care costs for COPD patients treated with 
1) inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) or long-acting mus-
carinic antagonist (LAMA) (non-triple) therapy, or 2) concurrent ICS/LABA+LAMA 
(triple) therapy. Post-treatment costs were aggregated by 4-week periods. Costs were 
estimated for ITT and AP treatment groups, using actual and weighted cost methods. 
Patients were censored for health plan disenrollment (possible after 6 months post-
index). In the AP analysis, patients were additionally censored for discontinuation of 
treatment. Weights were the inverse probability of remaining uncensored. Results: 
Study subjects numbered 5,475; 484 triple, 4,991 non-triple. Few patients disenrolled 
(n= 139) by one-year post-index. ITT cost estimates were similar for actual and 
weighted cost methods. ITT actual mean total costs were significantly higher for 
triple therapy patients (P= 0.01): $20,013 (standard deviation [SD], $12,865) for triple, 
and $18,468 (SD, $11,619) for non-triple. Censoring was heavy in the AP analysis. 
Probability for remaining uncensored during the 13th four-week period was 28.5% 
for triple patients and 22% for non-triple patients. AP actual mean total costs were 
considerably lower than ITT costs: $12,586 (SD, $9,991) for triple therapy, $8,688 (SD, 
$7,896) for ICS/LABA or LAMA. AP weighted mean total costs were $19,133 for triple 
therapy and $16,814 for non-triple. ConClusions: The weighted method allowed 
censored individuals to contribute cost information. AP analysis costs were lower 
than ITT costs, highlighting the impact of therapy discontinuation on analyses.
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objeCtives: The prevalence of COPD is higher and increases every year in China. 
To estimate hospital inpatient costs, LOS and complication among patients with 
osteoporosis fractures in China. Methods: Data were extracted by the discharge 
diagnosis of COPD from the China Health Insurance Research Association claim 
database which includes a nationwide, cross-sectional sampling of inpatients’ visits 
in 2011. Several complications were chosen from reference to our objective compli-
cation, the inpatients’ visits with these complication were chosen by their diagnosis 
and drug used because the records were not integrity. The descriptive analysis of 
LOS, total medical costs and other parameters were calculated. Continuous vari-
ables were examined by student’s t test for we showed all results with mean value 
and standard deviation. The statistical software was SPSS. Results: The analysis 
included 8667 hospitalizations (Male: 62.71%, Age: 72.08±74 years). Overall LOS and 
costs were 16.17±25.70 days and 7949.59±11782.33 RMB. Sample of hospitalization 
with complication of heart failure was most ( 2503 ), followed by atrial fibrilla-
tion (AF), diabetes mellitus (DM), hypertension, osteoporosis, ischemic heart 
disease(IHD). While, patients with osteoporosis had the most hospitalization 
cost (17352.85±29584.08 RMB), followed by IHD (17140.08±25472.15 RMB), anxiety-
depression (16399.81±22671.54 RMB), DM (13709.27±22288.66 RMB) and hyper-
tension (13564.59±20725.80 RMB). For hospitalization cost, Men’s was more than 
women’s (8366.42 ±11034.93 vs. 7248.65 ±12913.71 RMB p< 0.05), employee’s was more 
than residents’ (9126.86±13026.41 vs. 4887.81 ±6753.29 RMB p< 0.001), inpatients’ 
(age over than 80 ) was the most (9697.75±12238.17, RMB p< 0.001), east’s was the 
most(10853.62±14751.43 RMB p< 0.001), prefecture-level city’s was the most(8039.55 
±14584.93 RMB 0.05< p< 0. 1). ConClusions: Heart failure was a common com-
plication among COPD patients, and osteoporosis increased the hospitalization 
cost for COPD patients which might be for the surgery. Hospitalization cost varied 
significantly among different patients and area, expect different level of city. The 
relationship between cost and complication should be studied further in future.
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objeCtives: To systematically assess the global economic burden associated with 
symptomatic COPD. Methods: A systematic search of Embase®, MEDLINE®, 
EconLit® and LILACS® was conducted for last 10 years along with search of con-
ference proceedings for last 3 years. Non-randomised trials and observational stud-
infection, MXN$123 million for pneumococcal diseases, MXN$199 million for HPV, 
and MXN$258 million for B. pertussis. Cost offsets in Year 1 after adoption of the 
immunization program totaled MXN$23 million for RSV infection, MXN$38 million 
for pneumococcal diseases, MXN$133 million for HPV, and MXN$206 million for 
B. pertussis. ConClusions: This model suggests that targeting RSV prophylaxis 
to high-risk populations can lead to substantial cost offsets, which are consistent 
with or improve on the budget impact of other preventive health programs for 
childhood diseases in Mexico.
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objeCtives: Arformoterol tartrate inhalation solution (arformoterol) is a long-act-
ing beta2-agonist indicated for long-term maintenance treatment of bronchocon-
striction in patients with chronic obstructive pulmonary disease (COPD). Nebulized 
albuterol (albuterol) is a short acting beta-agonist indicated as rescue medication 
for acute COPD exacerbations, but often patients receive it in place of maintenance 
treatment. This analysis estimated total medical, pharmacy and rehospitalization 
costs for nebulized arformoterol compared with albuterol nebulized solution for 
the management of COPD in hospitalized patients. Methods: An economic model 
was built comparing health care resource utilization and rehospitalization costs 
for arformoterol and albuterol from the hospital perspective. Pharmacy costs were 
calculated on a cost per hospital stay basis and were determined by the number 
of doses, frequency of administration, and hospital length of stay (LOS). Pharmacy 
costs were based on publically available wholesale acquisition costs. Medical costs 
included COPD exacerbation hospitalization costs, rehospitalization costs, and 
respiratory therapy costs. Cost of COPD-related inpatient hospitalizations were 
calculated as the cost per day times the mean LOS. Rehospitalization costs were 
calculated using rehospitalization rates at 30, 90, and 180 days. Respiratory ther-
apy costs were based on the number of daily sessions for administration and the 
hourly rate of respiratory therapy. Results: Mean LOS was 4.4 days for arformoterol 
vs. 5.2 days for albuterol. Arformoterol had lower rates of rehospitalization at 30, 
90 and 180 days post-discharge, respectively (8.7% vs. 11.9%, 15.4% vs. 26.8% and 
31.7% vs. 38.2%). Total medical and pharmacy costs per treated patient for arfor-
moterol were $6,953 vs. $8,456 for albuterol, resulting in a savings of $1,503 per 
patient. Arformoterol yielded net savings of $338, $1,025, and $847 over albuterol 
in rehospitalization cost per treated patient at 30, 90 and 180 days, respectively. 
ConClusions: Total costs of arformoterol were less than albuterol nebulized solu-
tion due to lower hospitalization and rehospitalization costs.
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eConomiC BuRden assoCiated to toBaCCo in the BRazilian population
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objeCtives: To estimate the economic burden of lost productivity and health care 
resource use associated to tobacco in the Brazilian population among smoking 
and non-smoking/ex-smoking employees. Methods: A structured search was 
performed on MEDLINE database (via PubMed) using the MesH Database terms 
in accordance with the following terms ((“Costs and Cost Analysis” [Mesh]) AND 
(“Smoking” [Mesh]) AND (“ absenteeism” [Mesh]) AND (“presenteeism” [Mesh])), 
as well as the cost of absence days due to health events retrieved from national 
labor legislations; and average wage was retrieved from the Brazilian Institute for 
Geography and Statistics (IBGE) 2.013. Results: The disease costs related to tobacco 
are Cardiovascular disease (CVD) BRL 27,845.32; stroke BRL 20,591.24; Chronic 
obstructive pulmonary disease (COPD) BRL 21,328.59; pneumonia BRL 1,111.82; lung 
cancer BRL 67,225.83; other cancers BRL 85,524.46. When comparing the productivity 
and absence days, the smokers lose 62.1% more days than nonsmokers and 41.34% 
than ex-smokers, which corresponds to BRL 1,326.62 in terms of annual monetary 
average cost. Additionally, it was found that the life expectancy of male smokers 
corresponds to 75.30 years; for females, it already was 79.77 years. That means a 
loss of 5.03 and 4.5 years, respectively, when compared to the expected useful lives 
of the the nonsmoking population. ConClusions: Therefore, smoking employees 
can cost, on unproductive days, almost 3 times more than non-smokers and 2 times 
more than ex-smokers, besides the cost related to the treatment of stroke, COPD 
and CVD, and others.
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objeCtives: Acute respiratory tract infections caused by Streptococcus pneumoniae(SP) 
are a leading cause of morbidity and mortality in young children and the elderly. 
In 2002, Alberta introduced a pneumococcal universal immunization program for 
children, using Prevnar 7 (PCV7). In this study, we assess the economic impact of 
PCV7 on the Alberta health care system. Methods: Using active surveillance data 
from Alberta, we examine the net costs averted as a result of a decline in PCV7 
serotypes, accounting for the increase in costs due to serotype replacement. We 
also calculate the magnitude of herd immunity in terms of costs averted. Results: 
We find that following the introduction of PCV7 (2003-2008), the number of cases 
of invasive disease caused by vaccine serotypes declined significantly across all 
ages. Specifically, by 2008, there was considerable evidence of herd immunity as 
the incidence rates had declined nearly 100% across all ages. However, non-PCV7 
cases, on the other hand, increased. Assuming serotype replacement is a result of 
